- Home
- TCMD vs AGMB Comparison
TCMD vs AGMB Comparison
Compare TCMD & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCMD | AGMB |
|---|---|---|
| Founded | 1995 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.6M | 576.2M |
| IPO Year | 2016 | 2024 |
Fundamental Metrics
Financial Performance| Metric | TCMD | AGMB |
|---|---|---|
| Price | $27.18 | $6.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $36.33 | ★ $37.67 |
| AVG Volume (30 Days) | ★ 174.4K | 101.6K |
| Earning Date | 11-02-2026 | 11-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $9.49 | N/A |
| P/E Ratio | $43.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.53 | $6.52 |
| 52 Week High | $37.77 | $17.82 |
Technical Indicators
Market Signals| Indicator | TCMD | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 26.72 |
| Support Level | $23.14 | N/A |
| Resistance Level | $26.45 | $9.55 |
| Average True Range (ATR) | 0.98 | 0.77 |
| MACD | 0.12 | -0.07 |
| Stochastic Oscillator | 86.29 | 11.30 |
Price Performance
Historical ComparisonAbout TCMD Tactile Systems Technology Inc.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.